Ülevaade
Aktsiahinna muutus
24h
Praegune
Min
45.06
Max
47.35
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +37.6% upside |
Järgmine tulemuste avaldamine | 3. nov 2026 |
|---|
Uudiste sentiment
By Acuity
50%
50%
112 / 339 Pingereas Healthcare
Rigel Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
11. sept 2026, 19:46 UTC
Rigel Pharmaceuticals is higher today, influenced by CPI data and speculation about potential Federal Reserve interest rate hikes. The stock remains near its one-month trading range.
Loe
10. sept 2026, 23:21 UTC
Rigel Pharmaceuticals Inc is rising in after-market trading, reversing a three-session decline. No specific news was identified to explain this price action.
Loe
8. sept 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares are lower today, continuing a decline since Friday. The stock saw notable volatility but remains above its 20-day moving average.
Loe
1. sept 2026, 20:08 UTC
Rigel Pharmaceuticals Inc shares are higher today, reflecting strong market performance and robust momentum above the 20-day moving average. No specific news was identified.
Loe
31. aug 2026, 20:07 UTC
Rigel Pharmaceuticals is lower today as the market reacts to comments from Warsh at the Jackson Hole Economic Symposium regarding elevated inflation and potential rate hikes.
Loe
25. aug 2026, 20:07 UTC
Rigel Pharmaceuticals shares are advancing, supported by easing Treasury yields and lower oil prices, despite pulling back from earlier session highs.
Loe
24. aug 2026, 19:56 UTC
Rigel Pharmaceuticals Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.
Loe
21. aug 2026, 19:36 UTC
Rigel Pharmaceuticals Inc is trading higher, despite pulling back from an earlier session peak. The stock remains above its 20-day moving average.
Loe
20. aug 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday amid broader market pressures, though no specific news has been identified.
Loe
19. aug 2026, 20:02 UTC
Rigel Pharmaceuticals Inc is trading higher amid strong market activity and high volume, reflecting increased investor interest since Tuesday's close.
Loe
18. aug 2026, 22:01 UTC
Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.
Loe
17. aug 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.
Loe
14. aug 2026, 20:06 UTC
HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.
Loe
13. aug 2026, 19:16 UTC
Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.
Loe
11. aug 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.
Loe
7. aug 2026, 19:26 UTC
Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.
Loe
6. aug 2026, 20:06 UTC
Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.
Loe
5. aug 2026, 20:02 UTC
Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.
Loe
4. aug 2026, 23:01 UTC
Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.
Loe
3. aug 2026, 19:26 UTC
Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.
Loe
31. juuli 2026, 19:41 UTC
Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.
Loe
30. juuli 2026, 19:29 UTC
Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.
Loe
29. juuli 2026, 19:47 UTC
Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.
Loe
28. juuli 2026, 19:56 UTC
Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.
Loe
27. juuli 2026, 16:16 UTC
Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.
Loe
24. juuli 2026, 20:01 UTC
Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.
Loe
22. juuli 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.
Loe
21. juuli 2026, 17:26 UTC
Rigel Pharmaceuticals Inc shares are higher, reflecting positive sentiment in the biotechnology sector amid broader market gains, particularly in technology stocks.
Loe
Võrdlus sarnastega
Hinnamuutus
Rigel Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
12 kuu keskmine prognoos
Keskmine 65 USD 37.6%
Kõrge 85 USD
Madal 43 USD
Põhineb 4 Wall Streeti analüütiku instrumendi Rigel Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Hinnangu Konsensus
By TipRanks
Osta
4 ratings
2
Osta
2
Hoia
0
Müü
Põhineb 4 analüütiku instrumendi Rigel Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.
Sentiment
By Acuity
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
$